HomeQuestion
How would you approach a T3N1M0 mid rectal cancer that is MMR deficient?
2
2 Answers
Mednet Member
Medical Oncology · Mayo Clinic
About 2.7% of rectal adenocarcinoma are mismatch repair deficient (dMMR) (Papke Jr. et al., PMID 36322852) and locally advanced dMMR rectal cancers have a great response to immunotherapy. Six months of single agent Dostarlimab led to 100% complete clinical response in the phase 2 study including 14 ...